Arcadia denies administration but is “taking all appropriate steps”
Tenzo joins forces with Innovate UK to launch food waste initiative
“The UK hospitality industry generates over 1 million tonnes of food waste each year, amounting to over 4.5 million tonnes in CO2 emissions and costing the industry over £3.2 billion in lost revenue.
“On top of that, restaurants operate on a 3-5% average profit margin, making it one of the least profitable sectors in the country. The ongoing pandemic and subsequent lockdowns have also had a significant financial impact on the sector; restaurants need to save on costs now more than ever.
“By 2025, Tenzo will reduce annual UK hospitality food waste by over 180,000 tonnes – over 800,000 tonnes of CO2 and save the industry close to £100 million in costs”.
Tenzo’s business model is notably ambitious, but reflects the growing trend towards sustainability initiatives across a wide variety of sectors, from manufacturing to restaurant dining:
“We want to be in the pocket of every decision-maker in every restaurant and store on the globe, giving actionable insights to the right person, at the right time, and on the right device. Through our insights and forecasts, we aim to help every brick-and-mortar business become less wasteful, reducing the impact that humanity is having on the planet, and creating more efficient businesses that grow faster”.
Tenzo is already being used in over 10 different countries, including by famous brands such as Nando’s and TGI Friday’s.
Oil prices fall again with demand not expected to recover until ‘mid-2021’
FCA reprimands “reckless” Carillion for misleading investors
Caffè Nero launches CVA after pandemic “decimates” trading
ESMA warns fund managers to prepare for future adverse shocks
What did the report find?
The report identifies five “priority” areas for action which would enhance the preparedness of these fund categories:- Ongoing supervision of the alignment of the funds’ investment strategy
- Liquidity profile and redemption policy
- Ongoing supervision of liquidity risk assessment
- Fund liquidity profile reporting
- Increase of the availability and use of Liquidity Management Tools (LMTs)
- Supervision of valuation processes in a context of valuation uncertainty
Next steps for the ESMA
The ESMA said that it has “reinforced its coordination role regarding investment fund supervision” during the Covid-19 crisis, increasing its “frequent exchanges with NCAs [National Competent Authorities] on market developments and supervisory risks” – particularly on liquidity issues. In addition, the ESMA has also organised “regular data collection” on the use of LMTs by EEA [European Economic Area] UCITS and AIFs to ensure a more thorough overview of market performance. In response to a recommendation from the European Systemic Risk Board, the ESMA stated its intentions to “follow-up” with NCAs in relation to the “priority” areas 1, 2, and 5 in order to “foster supervisory convergence amongst NCAs in the area of liquidity risk management and valuation in stressed market conditions”. From a financial stability perspective, the ESMA said that its aforementioned priority areas should also “reduce the risk and the impact of collective selling by funds on the financial system, by addressing the liquidity and valuation risks at the level of the investment fund”. ESMA has confirmed it will continue to “monitor” this risk with regular assessments of the “resilience of the fund sector and participation to the development and operationalisation of the macroprudential framework for non-banks”.More than half of Brits in the dark about their credit score
Synairgen shares bounce 30% as SNG001 shown to accelerate COVID-19 recovery
Positive data has been reported over time, in July, September, and now in November, in greater detail. The trial was double-blind, randomised, placebo-controlled, and sought to test the efficacy and safety of inhaled SNG001 as a therapy for patients hospitalised with COVID-19. Patients received the SNG001 or placebo by inhalation via a mouthpiece once daily for 14 days, with the primary endpoint being the change in clinical condition, using the WHO Ordinal Scale for Clinical Improvement.
Synairgen said that, based on the trial, “SNG001 was shown to be well tolerated and patients who received the drug had greater odds of improvement and recovered more rapidly”. Across the scale of clinical improvement, patients receiving the SNG001 were seen to have greater odds of improvement, and were also more likely to recover to “no limitation of activity” during treatment. Most notably: in the placebo control group, there were three deaths. In the SNG001 sample, there were none.
Speaking on the trial data, company Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Lead Author, said:
“The results confirm our belief that interferon beta, a widely known drug approved for use in its injectable form for other indications, may have the potential as an inhaled drug to restore the lung’s immune response and accelerate recovery from COVID-19. This pH neutral, inhaled interferon beta-1a formulation (SNG001) provides high, local concentrations of the immune protein which boosts lung defences rather than targeting specific viral mechanisms. This might carry additional advantages of treating COVID-19 when it occurs alongside infection by another respiratory virus such as influenza or Respiratory Syncytial Virus that may well be encountered in the winter months.”
Following the announcement, Synairgen shares rallied by between 30% and 35%, up to more than 131p apiece at lunchtime on Friday 13/11/20. Until July, the company’s stock was trading for around half this price, but once the first SNG001 data was published, shares traded for as much as 246p.